<DOC>
	<DOCNO>NCT02461719</DOCNO>
	<brief_summary>The purpose clinical Study TJCS Eye Drops 0.05 % ( Cyclosporine ophthalmic nano-emulsion ) group Restasis Eye Drops 0.05 % ( Cyclosporine ophthalmic suspension ) group 12 week treatment , treatment group comparison evaluation efficacy safety Moderate Severe Dry Eye Disease .</brief_summary>
	<brief_title>Efficacy Safety Study TJCS Treatment Moderate Severe Dry Eye Syndromes</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>Male female , age 20 Patients moderate severe dry eye Screening eye , correct visual acuity 0.2 Screening visit within 4 week treat systemic cyclosporine topical cyclosporine ophthalmic solution . Screening visit within 2 month patient systemic ocular disorder affect test result ( ocular surgery , trauma , disease ) Intraocular pressure ( IOP ) &gt; 25 mmHg Patient use use punctual plug within 1 month . Patients contact lens .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>